VE 202

Drug Profile

VE 202

Alternative Names: VE-202

Latest Information Update: 04 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vedanta Biosciences
  • Class Anti-inflammatories
  • Mechanism of Action Immunomodulators; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammatory bowel diseases

Most Recent Events

  • 04 Oct 2016 Preclinical development for Autoimmune disorders is ongoing in USA
  • 19 Sep 2016 Vedanta Biosciences plans a clinical trial for Inflammatory bowel disease in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top